Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Summary 
Currently, Garry E. Menzel occupies the position of President, Chief Executive Officer & Director at TCR2 Therapeutics, Inc.

He is also on the board of Institute for Systems Biology, Epilepsy Therapy Project, Stoke Therapeutics, Inc. and Black Diamond Therapeutics, Inc. and Member-National Board at Epilepsy Foundation and Principal at Royal College of Art.

Dr. Menzel previously was Chief Operating Officer for Regulus Therapeutics, Inc., Chief Financial Officer of DaVita, Inc., Managing Director at Credit Suisse Group AG, Managing Director at The Goldman Sachs Group, Inc., Consultant at Bain & Co., Inc., Chief Strategy Officer for Axcella Health, Inc. and Research Assistant at Smithkline Beecham Plc.

Garry E. Menzel received an undergraduate degree from Imperial College London, an MBA from Stanford Graduate School of Business and a doctorate from St. John's College, Cambridge.


Current positions of Garry E. Menzel 
NameTitle Since
Stoke Therapeutics, Inc.
(Biotechnology & Medical Research)
Independent Director 2020
Black Diamond Therapeutics, Inc.
(Biotechnology & Medical Research)
Independent Director 2014
TCR2 Therapeutics Inc.
(Biotechnology & Medical Research)
President, Chief Executive Officer & Director 2016
Institute for Systems Biology Director-Emeritus 2013
Epilepsy Therapy Project Director -
Epilepsy Foundation Member-National Board 2003
Royal College of Art Principal -


Holdings of Garry E. Menzel 
NameEquities%Valuation
Black Diamond Therapeutics, Inc. (BDTX)
(Biotechnology & Medical Research)
76,6440.21%587,093 USD
TCR2 Therapeutics Inc. (TCRR)
(Biotechnology & Medical Research)
88,6120.23%558,256 USD
Stoke Therapeutics, Inc. (STOK)
(Biotechnology & Medical Research)
00.0000%0 USD


Garry E. Menzel: Personal Network 
Most Read News 
11/15PATRICK DRAHI : Altice founder Drahi seeks bigger stake in Britain's BT - sources
RE
11/23ELON MUSK : Tesla's Musk exercises more options, sells shares worth $1.05 billion
RE
11/15ELON MUSK : Analysis-Musk's $6 billion Tesla stock haul has charity circuit buzzing
RE
11/24JAMIE DIMON : Jamie Dimon jokes that JPMorgan will outlast China's Communist Party
RE
11/17HENRIK FISKER : Fisker unveils electric SUVs to beat Tesla over driving range
RE
11/16ELON MUSK : Tesla's Musk sells another 934,000 shares to pay taxes after exercising options - filing
RE
11/15WARREN BUFFETT : Buffett's Berkshire cuts U.S. drugmaker stakes, invests in drug royalty company
RE
11/16TED ROGERS : Rogers names Staffieri interim CEO as chair stamps authority after family feud
RE
11/26ELON MUSK : Tesla decides against state aid for German battery plant as Musk opposes subsidies
RE
11/15ELON MUSK : Tesla's Musk sells $930 mln in shares to cover stock option tax - filings
RE
More news


© 2021 People and Ownership :   
Garry E. Menzel : Connections